As acitretin may have potential as a novel therapeutic drug for AD due to its ability to increase sAPPα in the CSF of AD patients (37), we investigated whether acitretin, via activation of ADAM10, would increase the shedding of PrPC and decrease AβO binding. The gene discussed is ADAM10; the disease is Alzheimer disease.